MNK-795 is a controlled-release oral formulation of oxycodone and acetaminophen that has been studied for the management of moderate to severe acute pain.
The FDA grants priority review to drugs that offer significant improvements in the safety or effectiveness of a treatment when compared to standard applications.
More Articles on Pain Management:
Study: Prescription Painkiller Overdose Deaths in Women Spike 400% in 10 Years
Dr. Walter Schuyler Joins Pain Specialists of Charleston
Sibley Medical Center to Open Pain Management Clinic, Adds Dr. J. Richard Waggoner
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
